In this Axios column, Drew Altman wades in to the Medicare for All discussion focusing on the pros and cons of a critical but under-discussed feature of the proposals-they have no cost sharing.
- view as grid
- view as list
In this Axios column about the Texas court decision, Drew Altman shows that many provisions of the Affordable Care Act are even more popular than protections for pre-existing conditions, the issue which put Republicans on the defensive and helped Democrats in the midterm elections.
n an Axios column, , Drew Altman uncovers a new pre-existing conditions problem – seniors on Medicare denied Medigap because they have pre-existing conditions – and discusses solutions.
In an Axios column, Drew Altman analyzes the political pros and cons of Medicare for All and Medicare buy-in plans for Democrats, and how they may handle it in Congress and the presidential campaign.
In an Axios column, Drew Altman analyzes what the midterm election means for the health policy agenda between now and 2020–mostly political positioning and gridlock in Congress, with most of the action affecting people in the states.
Drew Altman analyzes the senior health care vote in his Axios column. This group, most likely to vote in the midterms, has more Democrats than Republicans and trusts Democrats more on health. They will give Democrats a real but modest advantage in the election.
With less than two weeks until Election Day, Drew Altman discusses health being the top issue, but not necessarily the top factor in voters’ 2018 decisions. He says the longer-term impact of health may be its continuing role in the debate leading up to the 2020 presidential race.
In this June 2018 post for The JAMA Forum, Larry Levitt examines the potential impact of the Trump Administration’s legal challenge to the Affordable Care Act’s protections for people with pre-existing conditions.
In this Axios column, Drew Altman shows that unlike the individual market, narrow networks are not common in the much larger group market, and discusses why and why it matters.
n this Axios column, Drew Altman presents a puzzle around corporate health costs: companies are talking like there is a crisis, but new data doesn’t really show it.